Table 3 Treatment regimen
From: Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases
Lesion size maxim. diameter (mm) | Single dose MIU | Stock solution (ml) | Duration of treatment (weeks) |
|---|---|---|---|
<5 | 0.6 | 0.2 | 2 |
>5 | 1.2 | 0.4 | 3 |
>10 | 3.0 | 1.0 | 4 |
>20 | 6.0 | 2.0 | 4 |
